deltatrials
Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06472050

Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study

Romosozumab Versus Denosumab in Patients With Glucocorticoid-induced Osteoporosis: a 2-year Extension Study of a Randomized Controlled Trial

Sponsor: Tuen Mun Hospital

Conditions Glucocorticoids Toxicity Osteoporosis
Interventions Denosumab Romosozumab
Updated 3 times since 2024 Last updated: Nov 19, 2024 Started: Aug 20, 2024 Primary completion: Dec 31, 2025 Completion: Mar 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Glucocorticoids Toxicity and Osteoporosis and is currently actively recruiting participants. Tuen Mun Hospital leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotNot Yet Recruiting~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshotNot Yet Recruiting~Dec 2024 – present · 19 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Dec 2024 — Present [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  2. Sep 2024 — Dec 2024 [monthly]

    Not Yet Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tuen Mun Hospital
Data source: Tuen Mun Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations